N-Piperidin-1-ylmethyl-acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-Piperidin-1-ylmethyl-acetamide
• 英文别名: N-(piperidin-1-ylmethyl)acetamide
• 化学式: C₈H₁₆N₂O
• 分子量: 156.228
• InChiKey: HBAHJARFTOJJDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乙酰胺 、 1-(piperidinomethyl)-1H-1,2,3-benzotriazole 在 sodium hydride 、 zinc(II) chloride 作用下， 以 二氯甲烷 为溶剂， 以61%的产率得到N-Piperidin-1-ylmethyl-acetamide
  参考文献：
  名称：

  Monoacylaminals by the Benzotriazole-Assisted Aminoalkylation of Amides

  摘要：

  DOI：

  10.1055/s-1998-2164

文献信息

• New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Roth Juergen Gerald

  公开号：US20070111981A1

  公开（公告）日：2007-05-17

  The present invention relates to (hetero)aryl compounds of general formula I wherein the groups and radicals A, B, Q, W, X, Y, Z, R 1 , R 2 , R 4a , R 4b , R 5a , R 5b , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的（杂）芳基化合物，其中A、B、Q、W、X、Y、Z、R1、R2、R4a、R4b、R5a和R5b基团和基团具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中的一种化合物的制药组合物。由于其MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，尤其是肥胖症、贪食症、厌食症、暴食症和糖尿病。
• Novel quinolonecarboxylic acid derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0342675A2

  公开（公告）日：1989-11-23

  Novel compounds of the present invention are repre­sented by the general formula (I) wherein R₁ is hydrogen atom or amino, R₂ is fluorine atom or methoxy, R₃ is hydrogen atom or a lower alkyl having 1 to 3 carbon atoms, and n is 0 or 1. The compounds of the general formula (1) exhibit higher antibacterial activity with fewer side-effects than known quinolone antibiotics such as ofloxacin and norfloxacin. Further, the compounds having the general formula (1) have reduced phototoxicity which normally accompanies 6,8-difluoroquinoline antibiotics.

  本发明的新型化合物由通式(I)表示 其中 R₁ 是氢原子或氨基，R₂ 是氟原子或甲氧基，R₃ 是氢原子或具有 1 至 3 个碳原子的低级烷基，n 是 0 或 1。与已知的喹诺酮类抗生素（如氧氟沙星和诺氟沙星）相比，通式（1）化合物具有更高的抗菌活性和更少的副作用。此外，通式（1）化合物还降低了通常伴随 6,8-二氟喹啉类抗生素出现的光毒性。
• Sharifi; Mohsenzadeh; Naimi-Jamal, Journal of Chemical Research - Part S, 2000, # 8, p. 394 - 396
  作者：Sharifi、Mohsenzadeh、Naimi-Jamal

  DOI：——

  日期：——
• 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
  申请人：Andrés-Gil José Ignacio

  公开号：US20140147386A1

  公开（公告）日：2014-05-29

  The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE 10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.